Ledger.Open graph →
SEC Form D · filed March 16, 2018

Aimmune Therapeutics, Inc

Offering
$156.7M
Sold
$156.7M
Exemption
Rule 506(b)
Industry
Other Health Care
Location
BRISBANE, CA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (26)

Mark D. Mcdade · South San Francisco, CADirectorPatrick G. Enright · Menlo Park, CADirectorMark T. Iwicki · Brisbane, CADirectorEric H. Bjerkholt · Brisbane, CAExecKathryn E. Falberg · Broomfield, CODirectorJeffrey H. Knapp · Brisbane, CAExecDaniel C. Adelman · Brisbane, CAExecSusan E. Barrowcliffe · Brisbane, CAExecStephen G. Dilly, Jr · San Mateo, CAExec · DirectorGregory E. Behar · Brisbane, CADirectorMary M. Rozenman · Brisbane, CAExecStacey D. Seltzer · New York, NYDirectorDouglas T. Sheehy · Brisbane, CAExecMark D. Mcdade · South San Francisco, CADirectorKathryn E. Falberg · Brisbane, CADirectorJeffrey H. Knapp · Brisbane, CAExecPatrick G. Enright · Plymouth, MIDirectorDaniel C. Adelman · Brisbane, CAExecSusan E. Barrowcliffe · Brisbane, CAExecStephen G. Dilly, Jr · San Mateo, CAExec · DirectorGregory E. Behar · Brisbane, CADirectorMark T. Iwicki · Brisbane, CADirectorMary M. Rozenman · Brisbane, CAExecStacey D. Seltzer · New York, NYDirectorEric H. Bjerkholt · South San Francisco, CAExecDouglas T. Sheehy · Brisbane, CAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗